Veeva price target raised to $250 from $227 at Barclays

Barclays analyst Saket Kalia raised the firm’s price target on Veeva to $250 from $227 and keeps an Overweight rating on the shares. The results from DSY’s Medidata business combined with Veeva’s six top 20 pharma wins in electronic data capture point to some potential share shift in the EDC market, which is the biggest part of Veeva’s estimated $3B clinical total addressable market and where Medidata is the market share leader, the analyst tells investors in a research note.